Patient P-01663

Synthetic patientNBL-101 · Day 108 · 35–44 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Stable

Nutritional resilience

Declining

Discontinuation risk

66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 No meaningful change — Dietary Support Protocol NP-02
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 51 SC-12 recommended — Supportive Compound SC-12
Day 52 Patient accepted — Started SC-12 in the companion
Day 58 GI-04 recommended — GI Support Protocol GI-04
Day 58 GI symptom burden −17% vs expected — Supportive Compound SC-12
Day 59 Patient accepted — Started GI-04 in the companion
Day 64 Tolerance state changed — Unstable → Improving
Day 67 GI symptom burden −30% vs expected — GI Support Protocol GI-04
Day 73 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Nutritional resilience-11
GI instability+9
Toxicity+5
Treatment adherence-3

What helped?

Dietary Support Protocol NP-02Day 31
Result: no meaningful change
Supportive Compound SC-12Day 51
Result: symptom burden −17%
GI Support Protocol GI-04Day 58
Result: symptom burden −30%

LIFE OS recommendation

Monitoring Escalation ME-01

82%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

38.7/100

improving · -9.1 vs previous 14 d

Toxicity

Blood

40.5/100

worsening · +4.4 vs previous 14 d

Sleep quality

Wearable

40.5/100

improving · +2.5 vs previous 14 d

Energy level

Daily log

3.9/10

stable · +0.2 vs previous 14 d

Stress level

Daily log

5.5/10

stable · -0.0 vs previous 14 d

Steps

Wearable

6,920

improving · +396 vs previous 14 d

Adherence

Companion

53.2 %

worsening · -5.0 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 46 from the failing basin, 41 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 69 similar · onset 3 d · confidence 70%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 70%

Would not help

NP-02 Dietary Support Protocol
already tried, no meaningful change
Keep fat low
GI +6.7 next day on high-intake days · n 20
Keep histamine low
GI +6.2 next day on high-intake days · n 24
Keep fibre low
GI +6 next day on high-intake days · n 20

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+6.7detractor · 95%
Histamine load
+6.2detractor · 95%
Insoluble fibre
+6detractor · 95%
Alcohol
+1.1no signal · 22%
Spicy / capsaicin
-0.3no signal · 15%
Simple carbohydrates
-0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 42
- WearableHRV 23 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 39/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
Autonomic recovery ↓25
- WearableResting HR 85 bpm
Drug metabolism and exposure ↑20
- BloodToxicity index 41

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 39/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 28 ms
Sleep: 7.4 h
Steps: 7,873
Resting HR: 79 bpm

Daily log: GI score 39, nutritional resilience 46, adherence 53.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01804	28%	S19	AD-05	improved	61
P-01679	26%	S12	AD-05	no change	39
P-01377	25%	S11	AD-05	no change	42
P-01483	25%	S14	AD-05	no change	35
P-01350	26%	S19	BR-03	no change	34
P-01442	35%	S13	CR-01	improved	61
P-01371	34%	S06	CR-01	improved	63
P-01696	33%	S20	CR-01	improved	59
P-01835	31%	S17	CR-01	improved	56
P-01388	30%	S17	CR-01	improved	59
P-01708	29%	S07	CR-01	improved	59
P-01430	28%	S05	CR-01	improved	54